Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. No user-facing content or layout changes are evident.
    Difference
    0.0%
    Check dated 2026-04-16T10:14:22.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-18T16:45:37.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    A backend version update shows revision v3.4.3 replacing v3.4.2. No visible changes to study content or user-facing features.
    Difference
    0.0%
    Check dated 2026-03-11T14:43:46.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now shown on the page. Notices about government funding lapse and an older Revision: v3.4.1 have been removed.
    Difference
    0.4%
    Check dated 2026-02-11T05:51:28.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    A government funding lapse notice about site status was added, and the page now displays the updated revision version 3.4.1 (replacing 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T05:38:36.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option and updated metadata with 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' plus a new revision tag 'Revision: v3.4.0', while removing older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T03:30:41.000Z thumbnail image

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.